Denosumab in hemodialysis patients with osteoporosis : comparison of usefullness between high and low turnover bone.

Denosumab in hemodialysis patients with osteoporosis : comparison of usefullness between high and low turnover bone. - Denosubmab in hemodialysis patients with osteoporosis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011999

Enrollment

Registered

2014-03-01

Start date

2013-12-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

denosumab is admininistered in 60mg by subctaneous injection in each 6 month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients diagnosed with osteoporosis

Exclusion criteria

Exclusion criteria: bedridden patients tube feeding patients hypocalcemia patients

Design outcomes

Primary

Measure	Time frame
1.improvement of BMD 2.prevalent of bone fracture	—

Secondary

Measure	Time frame
improvement of turn over of the bone i-PTH,P,Ca,BAP,TRAPC5b	—

Countries

Japan

Contacts

Public ContactMasaki Aono

Sato Junkanki hospital vice-principal

masaki-aono@satohp.co.jp089-933-0808

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026